ReviewBreast disease2010
BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.
Review in Breast disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Review
- Mutational profiles of spontaneous and radiation-related mammary carcinomas in a rat model of Brca1 haploinsufficiency.Scientific reports · 2026Article
- Article
- Restoration of TFPI2 by LSD1 inhibition suppresses tumor progression and potentiates antitumor immunity in breast cancer.Cancer letters · 2024Article
- The Anti-Cancer Activity of the Naturally Occurring Dipeptide Carnosine: Potential for Breast Cancer.Cells · 2023Review
- Unlocking Translational Potential: Conditionally Reprogrammed Cells in Advancing Breast Cancer Research.Cells · 2023Review
- Esr1 but Not CYP19A1 Overexpression in Mammary Epithelial Cells during Reproductive Senescence Induces Pregnancy-Like Proliferative Mammary Disease Responsive to Anti-Hormonals.The American journal of pathology · 2023Article
- Brca1Cancer science · 2022Article
- The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.Antioxidants (Basel, Switzerland) · 2022Review
- Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development.Scientific reports · 2018Article
- BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.Oncogenesis · 2017Article
- Review
- Responsiveness ofCancer prevention research (Philadelphia, Pa.) · 2017Article
- The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis.Nature communications · 2016Article
- Primary cancer cell culture: mammary-optimized vs conditional reprogramming.Endocrine-related cancer · 2016Article
- Hereditary cancer syndromes as model systems for chemopreventive agent development.Seminars in oncology · 2016Review
- A DNA methylation-based definition of biologically distinct breast cancer subtypes.Molecular oncology · 2015Article
- Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.Carcinogenesis · 2015Article
- Article
- Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer.Cancer discovery · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Genetically engineered mice along with allograft and xenograft models can be used to effectively model triple negative breast cancer both for studies of pathophysiology as well as preclinical prevention and therapeutic drug studies. In this review eight distinct genetically engineered mouse models of BRCA1 deficiency are discussed in relationship to the generation of triple negative mammary cancer. Allograft models derived from some of these genetically engineered mice are considered and xenograft models derived from breast cancers that developed from BRCA1 mutation are presented. Examples of the use of genetically engineered, allograft and xenografts models for preventive and therapeutic studies are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.